The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection
Objectives: Evaluation of the intravesical instillation of doxorubicin for its effect on disease recurrence for patients with non-invasive bladder tumour. Methods: The trial was performed at Al Assad University Hospital in Lattakia, Syria and included patients with non–invasive bladder tumours who w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sultan Qaboos University
2009-04-01
|
| Series: | Sultan Qaboos University Medical Journal |
| Subjects: | |
| Online Access: | https://journals.squ.edu.om/index.php/squmj/article/view/1401 |
| _version_ | 1828796455592132608 |
|---|---|
| author | Musa I Al-Gallab Louai A Naddaf Mohamad R Kanan |
| author_facet | Musa I Al-Gallab Louai A Naddaf Mohamad R Kanan |
| author_sort | Musa I Al-Gallab |
| collection | DOAJ |
| description | Objectives: Evaluation of the intravesical instillation of doxorubicin for its effect on disease recurrence for patients with non-invasive bladder tumour. Methods: The trial was performed at Al Assad University Hospital in Lattakia, Syria and included patients with non–invasive bladder tumours who were managed with transurethral resection and induction and maintenance therapy with intravesical doxorubicin. They were followed up by cystoscopy every 3 months for 2 years and every 6 months thereafter with special emphasis on recurrence rates. Results: The trial included 85 patients with non–invasive bladder tumours: 23 with non-invasive papillary carcinoma (Stage Ta), 62 with tumour invading subepithelial connective tissue (Stage T1). Twelve patients had well differentiated tumours (Grade 1), 48 were moderately differentiated (Grade 2), 25 were poorly differentiated (Grade 3). The total recurrence rate was 23%. The rates of recurrence were 56% in Grade 3 and 0% in Grade 1. The recurrence rate was 41% in patients with large tumours versus 17% in those with small tumours; 44% in those with multiple tumours compared to 18% in those with solitary tumours; 30% of Stage Ta tumours recurred and 21% of Stage T1 tumours. Conclusion: In short term follow-up, our rate of recurrence was 23% compared to 54% in multicentre international studies without the intravesical adjuvant; thus adjuvant intravesical doxorubicin was shown to reduce the recurrence of superficial bladder cancer. Tumour grade, size and number were shown to be prognostic factors for recurrence. |
| first_indexed | 2024-12-12T04:23:07Z |
| format | Article |
| id | doaj.art-00eee3a05028486f8f94e318915ce8ff |
| institution | Directory Open Access Journal |
| issn | 2075-051X 2075-0528 |
| language | English |
| last_indexed | 2024-12-12T04:23:07Z |
| publishDate | 2009-04-01 |
| publisher | Sultan Qaboos University |
| record_format | Article |
| series | Sultan Qaboos University Medical Journal |
| spelling | doaj.art-00eee3a05028486f8f94e318915ce8ff2022-12-22T00:38:16ZengSultan Qaboos UniversitySultan Qaboos University Medical Journal2075-051X2075-05282009-04-019153581329The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral ResectionMusa I Al-Gallab0Louai A Naddaf1Mohamad R Kanan2Division of Urology, Department of Surgery, Al Assad University Hospital, Faculty of Medicine, Tishreen University, Lattakia, SyriaDivision of Urology, Department of Surgery, Al Assad University Hospital, Faculty of Medicine, Tishreen University, Lattakia, SyriaDivision of Urology, Department of Surgery, Al Assad University Hospital, Faculty of Medicine, Tishreen University, Lattakia, SyriaObjectives: Evaluation of the intravesical instillation of doxorubicin for its effect on disease recurrence for patients with non-invasive bladder tumour. Methods: The trial was performed at Al Assad University Hospital in Lattakia, Syria and included patients with non–invasive bladder tumours who were managed with transurethral resection and induction and maintenance therapy with intravesical doxorubicin. They were followed up by cystoscopy every 3 months for 2 years and every 6 months thereafter with special emphasis on recurrence rates. Results: The trial included 85 patients with non–invasive bladder tumours: 23 with non-invasive papillary carcinoma (Stage Ta), 62 with tumour invading subepithelial connective tissue (Stage T1). Twelve patients had well differentiated tumours (Grade 1), 48 were moderately differentiated (Grade 2), 25 were poorly differentiated (Grade 3). The total recurrence rate was 23%. The rates of recurrence were 56% in Grade 3 and 0% in Grade 1. The recurrence rate was 41% in patients with large tumours versus 17% in those with small tumours; 44% in those with multiple tumours compared to 18% in those with solitary tumours; 30% of Stage Ta tumours recurred and 21% of Stage T1 tumours. Conclusion: In short term follow-up, our rate of recurrence was 23% compared to 54% in multicentre international studies without the intravesical adjuvant; thus adjuvant intravesical doxorubicin was shown to reduce the recurrence of superficial bladder cancer. Tumour grade, size and number were shown to be prognostic factors for recurrence.https://journals.squ.edu.om/index.php/squmj/article/view/1401intravesical instillationsdoxorubicinnon-invasive bladder cancer. |
| spellingShingle | Musa I Al-Gallab Louai A Naddaf Mohamad R Kanan The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection Sultan Qaboos University Medical Journal intravesical instillations doxorubicin non-invasive bladder cancer. |
| title | The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection |
| title_full | The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection |
| title_fullStr | The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection |
| title_full_unstemmed | The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection |
| title_short | The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection |
| title_sort | management of non invasive bladder tumours with doxorubicin intravesical instillation after transurethral resection |
| topic | intravesical instillations doxorubicin non-invasive bladder cancer. |
| url | https://journals.squ.edu.om/index.php/squmj/article/view/1401 |
| work_keys_str_mv | AT musaialgallab themanagementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection AT louaianaddaf themanagementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection AT mohamadrkanan themanagementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection AT musaialgallab managementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection AT louaianaddaf managementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection AT mohamadrkanan managementofnoninvasivebladdertumourswithdoxorubicinintravesicalinstillationaftertransurethralresection |